Can P-glycoprotein influence the bioavailability of iminosugar-based glucosylceramide synthase inhibitors?

@article{NorrisCervetto2006CanPI,
  title={Can P-glycoprotein influence the bioavailability of iminosugar-based glucosylceramide synthase inhibitors?},
  author={Edward Norris-Cervetto and Terry D. Butters and Catherine Rucker Martin and Szabolcs Modok and Raymond A. Dwek and Richard Callaghan},
  journal={European journal of pharmacology},
  year={2006},
  volume={530 3},
  pages={195-204}
}
Recently developed glucosylceramide synthase inhibitors with enhanced hydrophobicity display increased bioavailability in the central nervous system (CNS). Have these improvements come at a potential risk given that the improved glucosylceramide synthase inhibitors bear the hallmarks of P-glycoprotein substrates? This question warrants attention given the… CONTINUE READING